Generation Bio reports Q3 EPS (43c), consensus (50c)

Reports Q3 revenue $2.15M, consensus $1.09M. Reports cash, cash equivalents, and marketable securities were $291M as of September 30, compared to $279.1M as of December 31, 2022. The company continues to believe that its cash position will fund its operating plan into 2026. It said, “The recent advances in our immune-quiet DNA (iqDNA) and cell-targeted lipid nanoparticle (ctLNP) platforms represent two breakthroughs in the field of genetic medicine. Our iqDNA has been shown to evade host innate immune sensors in mice and non-human primates (NHPs), addressing a central challenge for non-viral DNA therapeutics. Our ctLNP delivery system overcomes an equally central challenge for delivery, which is the highly selective targeting of DNA and/or RNA cargo to extrahepatic tissues and cell types. The foundational properties of iqDNA and our ctLNP have translated across mice and NHPs, and we now look forward to generating additional NHP data with therapeutic payloads for each platform.”